Public Comment | Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications | August 1, 2024 Share
Peer Review | An Analysis of Dosing-Related Postmarketing Requirements for Novel Oncology Drugs Approved by the U.S. Food and Drug Administration, 2012–2022 | December 12, 2023 Share
White Paper | 2023 Annual Meeting | Interpreting Data from Dose-Finding Studies in Early Phase Oncology Trials to Determine the Optimal Dose | November 14, 2023 Share
White Paper | 2022 Annual Meeting | Supporting a Patient-Centric Approach to Dose Optimization in Oncology: The Essential Role of Patient-Reported Outcomes (PROs) | November 18, 2022 Share
White Paper | 2021 Annual Meeting | Optimizing Dosing in Oncology Drug Development | February 3, 2022 Share
